

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

INSIDE INFORMATION:

**(1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED DECEMBER 31, 2025;
(2) POSTPONEMENT OF BOARD MEETING; AND
(3) SUSPENSION OF TRADING**

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**” or “**Ab&B Bio-Tech**”, together with its subsidiary, the “**Group**”) pursuant to Rule 13.09(2)(a) and Rule 13.49(3)(i) of the Rules (the “**Listing Rules**”) Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)

Reference is made to the announcement of the Company dated March 19, 2026 (the “**Announcement**”), in relation to the meeting of the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company originally scheduled to be held on Tuesday, March 31, 2026 for the purposes of, among other matters, considering and approving the audited annual results of the Group for the financial year ended December 31, 2025 (the “**2025 Annual Results**”) and its publication, and considering the recommendation for the payment of a final dividend (if any). Capitalised terms used herein shall have the same meanings as those defined in the Announcement, unless the context herein requires otherwise.

DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish an announcement for the 2025 Annual Results (the “**2025 Annual Results Announcement**”) on a date not later than three months after the end of the financial year of the Company, namely, on or before March 31, 2026. Under Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2025 Annual Results shall be based on the Company’s financial statements for the financial year ended December 31, 2025, which shall be agreed with the Company’s auditors.

The Company wishes to inform the shareholders and potential investors of the Company that the publication of the 2025 Annual Results Announcement will be delayed, as the audit of the financial statements of the Group for the year ended December 31, 2025 has not been completed. The delay is attributable to, among other matters, the fact that the audit procedures and the related internal enquiries by the audit committee of the Board with respect to certain investments in funds and certain consultancy payments have not been completed and are subject to further investigation. The Group will target to finalize these matters and coordinate with the Company's auditors to complete the outstanding audit procedures, and to provide all necessary documentation and assessments as soon as reasonably practicable. The delay in publication of the 2025 Annual Results constitutes non-compliance of Rule 13.49(1) of the Listing Rules.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results within the prescribed timeframe, it must announce its results based on the financial results which have yet to be agreed with the auditors (so far as the information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended December 31, 2025 at this stage as it may not accurately reflect the financial performance and/or position of the Group, and their publication may create unnecessary confusion and may be misleading to the shareholders and potential investors of the Company in the interim period.

POSTPONEMENT OF BOARD MEETING

Due to the aforesaid delay in the publication of the 2025 Annual Results, the Board meeting originally scheduled to be held on Tuesday, March 31, 2026 for the purposes of, among other matters, considering and approving the 2025 Annual Results and its publication, and considering the recommendation for the payment of a final dividend (if any), will be postponed to another date to be fixed and announced by the Board.

SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, if an issuer fails to publish periodic financial information in accordance with the Listing Rules on a timely basis, the Stock Exchange will normally require a suspension of trading in the issuer's securities until the issuer publishes an announcement containing the requisite financial information. Accordingly, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 until the Company publishes the 2025 Annual Results.

The Company will announce separately in due course (i) the date of the Board meeting to consider and approve the 2025 Annual Results; (ii) the date of publication of the 2025 Annual Results Announcement; and (iii) significant developments.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of our Board and general manager

Hong Kong, March 31, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun and Mr. CHEN Chengbei as independent non-executive Directors.